ArticleCancer cell2016

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

Rony Dahan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.